Lipocine Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, X1, 84108
Mailing Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, X1, 84108
Phone
801 994 7383
Fiscal Year End
1231
EIN
990370688
Financial Overview
FY2025 FY
$11.20M
Revenue
$21.00M
Stockholders' Equity
$6.21M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | April 7, 2026 | View on SEC |
| 4 Insider stock transaction report | April 6, 2026 | View on SEC |
| 4 Insider stock transaction report | April 6, 2026 | View on SEC |
| 8-K Current report of material events | April 2, 2026 | View on SEC |
| 8-K Current report of material events | April 2, 2026 | View on SEC |
| 4 Insider stock transaction report | April 2, 2026 | View on SEC |
| 10-K Annual financial report | March 10, 2026 | View on SEC |
| 8-K Current report of material events | March 10, 2026 | View on SEC |
| 8-K Current report of material events | March 4, 2026 | View on SEC |
| 424B5 Prospectus supplement | February 26, 2026 | View on SEC |
Annual Reports
10-K
March 10, 2026
- LPC-101, the most advanced drug candidate, is in Phase 2 trials with top-line data expected mid-2026, marking a significant step towards potential regulatory submission.
- Reported a 15% increase in total revenue to $7.5 million for fiscal year 2025, primarily driven by licensing agreements and royalties.
Insider Trading
BUY
2 insiders
4 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.